ClinicalTrials.gg
CompletedNCT01838083Updated Aug 13, 2013

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

A Phase 1 interventional study of Insulin glargine new formulation HOE901 in Type1 Diabetes, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2013-08-13.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.

Enrollment
38th of 60
50 · median 86
Started
2013
with 1 other
Phase 1
20 of 67
none open now
Registered
33rd of 67
by date

Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 38th largest by enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2013, is one of 20 in phase 1, and was the 33rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Diabetes Mellitus, Type 1 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate equivalence in exposure to insulin glargine given as test formulation T and reference formulation R in steady state conditions after 6 once-daily subcutaneous (SC) doses

Secondary Objective:

  • To assess relative Pharmacodynamic activity of the insulin glargine test formulation T to the insulin glargine reference formulation R in steady state conditions after 6 once-daily SC doses
  • To assess the safety and tolerability of the test and reference formulations of two new insulin glargine formulations
Read the detailed description

Total study duration per subject: 29 to 64 days including screening visit

Duration of each part of the study for one subject:

  • Screening: 3 to 21 days before 1st dosing (Day -21 to Day -3)
  • Treatment Period 1 and 2: 8 days (dosing on 6 days)
  • Washout between last/1st dosing days of the treatment periods: 7-21 days (preferentially 7 days) End-of-Study Visit: 7-10 days after last dosing
03

Conditions studied

  • Type1 Diabetes
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, between 18 and 64 years of age, inclusive, with diabetes mellitus type 1 for more than one year
  • Total insulin dose of \< 1.2 U/kg/day
  • Minimum usual basal insulin dose ≥ 0.2 U/kg/day
  • Body weight between 50.0 kg and 110.0 kg, between 18.5 and 30.0 kg/m2 inclusive
  • Fasting negative serum C-peptide (\< 0.3 nmol/L)
  • Glycohemoglobin () ≤ 75 mmol/mol [≤ 9.0%]
  • Stable insulin regimen for at least 2 months prior to inclusion in study
  • Certified as otherwise healthy for Type-1 Diabetes mellitus patient
  • Laboratory parameters within the normal range
  • Women of with negative pregnancy test and use of a highly effective method or women with confirmed status

Exclusion criteria

Exclusion criteria:

  • Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic (apart from diabetes mellitus type 1), hematological, neurological, psychiatric, systemic (affecting the body as a whole), ocular, gynecologic (if female), or infectious disease; any acute infectious disease or signs of acute illness.
  • More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months
  • Frequent severe headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month)
  • Symptomatic hypotension (whatever the decrease in blood pressure), or asymptomatic postural hypotension defined by a decrease in systolic blood pressure equal to or greater than 20 mmHg within three minutes when changing from the supine to the standing position
  • Presence or history of a drug allergy or clinically significant allergic disease according to the Investigator's judgment
  • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
  • Presence or history of drug or alcohol abuse (alcohol consumption > 40 grams / day)
  • If female, pregnancy (defined as positive Beta Human Chorionic Gonadotropin test), breast-feeding
  • Known to insulin glargine or of the study drug
  • Any history or presence of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in first degree relatives (parents, siblings or children)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Insulin glargine new formulation (test T formulation)

    Once daily for 6 days

    Drug: Insulin glargine new formulation HOE901

  • Experimental
    Insulin glargine new formulation (reference R formulation)

    Once daily for 6 days

    Drug: Insulin glargine new formulation HOE901

Interventions

  • DrugInsulin glargine new formulation HOE901

    Pharmaceutical form: solution Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24) after dosing on Day 6

    Time frame: 24-hours (D6 to D7)

Secondary outcomes

  1. Maximum insulin concentration (INS-Cmax)

    Time frame: 24-hours (D6 to D7)

  2. Time to INS-Cmax (INS-tmax)

    Time frame: 24-hours (D6 to D7)

  3. Time to reach 50% of INS-AUC0-24 (T50%-INS-AUC0-24)

    Time frame: 24-hours (D6 to D7)

  4. Area under the body-weight-standardized Glucose Infusion Rate (GIR) within 24 hours (GIR-AUC0-24h) after dosing on Day 6 during the clamp

    Time frame: 24-hours (D6 to D7)

  5. Maximum smoothed body weight standardized glucose infusion rate (GIRmax)

    Time frame: 24-hours (D6 to D7)

  6. Time to GIRmax (GIR-Tmax)

    Time frame: 24-hours (D6 to D7)

  7. Time to reach at least 50% of GIR-AUC0-24 (T50%-GIR-AUC0-24)

    Time frame: 24-hours (D6 to D7)

  8. Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different prespecified blood glucose levels)

    Time frame: 24-hours (D6 to D7)

  9. Safety as measured by adverse events/serious adverse events, ohypoglycemia events, physical examinations, clinical laboratory, electrocardiograms, vital signs, injection site reactions and anti-insulin antibodies.

    Time frame: up to 9 weeks

07

Study locations

1 site
  • Investigational Site Number 276001
    Neuss, 41460, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2013
First posted
Apr 23, 2013
Start
Apr 2013
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Last update
Aug 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01838083
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 23, 2013
Start date
Apr 2013
Primary completion
Aug 2013
Completion
Aug 2013
Last update
Aug 13, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion